Top Markets
Coin of the day
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Rang in Aktien #40468
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Aktienkurs
$0.00204105
Marktkapitalisierung
$138.92K
Veränderung (1 Tag)
5.63%
Veränderung (1 Jahr)
-60.44%
Land
GB
Handel Solvonis Therapeutics plc (SVNS)

Kategorie

Preis SVNS mit Marktkapitalisierung von B
Solvonis Therapeutics plc Solvonis Therapeutics plc
SVNS
$0.00204105
Marktkapitalisierung von Solvonis Therapeutics plc(SVNS)
Marktkapitalisierung: $138.92K
Mit Stand August 2026 hat Solvonis Therapeutics plc eine Marktkapitalisierung von $138.92K. Das macht Solvonis Therapeutics plc laut unseren Daten zum 40468th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Solvonis Therapeutics plc von 2022 bis 2026
SVNS im Vergleich zu den Top 5 der beliebtesten stocks
Preis für SVNS Vermögenswert B Marktkapitalisierung von B Ergebnisse
Solvonis Therapeutics plc Solvonis Therapeutics plc
$80,358.71 $138.92K
$5.470T +3,937,121,289.65%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$65,648.98 $138.92K
$4.468T +3,216,428,044.48%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$61,303.54 $138.92K
$4.173T +3,003,525,872.49%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$54,361.71 $138.92K
$3.700T +2,663,415,733.27%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$41,936.14 $138.92K
$2.854T +2,054,633,061.29%